Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 16/20 | 0.67 |
| ▸ | AURKB | Q96GD4 | 10/20 | 0.67 |
| ▸ | GSK3B | P49841 | 8/20 | 0.59 |
| ▸ | SRC | P12931 | 6/20 | 0.53 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.51 |
| ▸ | GSK3A | P49840 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.48 |
| ▸ | JAK1 | P23458 | 3/20 | 0.48 |
| ▸ | TYK2 | P29597 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.48 |
| ▸ | JAK3 | P52333 | 3/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL174645 | 0.87 | AURKA (0.72) | AURKAAURKBGSK3BSRCEIF2AK2 | |
| SCHEMBL173666 | 0.81 | AURKA (0.73) | AURKAAURKBGSK3BSRCEIF2AK2 | |
| SCHEMBL28301245 | 0.81 | AURKA (1.00) | AURKAAURKBGSK3BSRCEIF2AK2 | |
| SCHEMBL721731 | 0.80 | AURKA (0.44) | AURKAAURKBGSK3BSRCEIF2AK2 | |
| SCHEMBL173501 | 0.79 | AURKA (0.88) | AURKAAURKBGSK3BSRCEIF2AK2 | |
| SCHEMBL160645 | 0.78 | AURKA (0.71) | AURKAAURKBGSK3BSRCEIF2AK2 | |
| SCHEMBL174480 | 0.76 | AURKA (0.84) | AURKAAURKBGSK3BSRCEIF2AK2 | |
| SCHEMBL802034 | 0.75 | AURKA (0.69) | AURKAAURKBGSK3BSRCEIF2AK2 | |
| SCHEMBL174477 | 0.75 | AURKA (0.79) | AURKAAURKBGSK3BSRCEIF2AK2 | |
| SCHEMBL12430500 | 0.75 | AURKA (1.00) | AURKAAURKBGSK3BSRCEIF2AK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633207-B2 | Quinazoline compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633207-B2 | Quinazoline compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633207-B2 | Quinazoline compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2014-01-21 | — | — | US | disclosed |
| EP-2611789-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030948-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030948-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20120053174-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2012-03-01 | — | — | US | disclosed |
| US-20120053174-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053174-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | JAK3, JAK2, TYK2 | AURKA 589/4885AURKB 404/4885GSK3B 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.